Benitec Biopharma Limited

The Directors of Benitec Limited (ASX:BLT)(PINK:BNIKF) announced today that it has issued a further 13,222,222 ordinary shares and 13,222,222 unlisted options to its major shareholder following the investment of a further A$595,000 by Dr Christopher Bremner.

Leading developer of RNA interference (RNAi)-based therapeutics Benitec Limited (ASX:BLT)(PINK:BNIKF) announced today that Dr Amrita Krishnan, had presented a poster on the human HIV trial at the American Society of Hematology conference held in San Francisco CA USA.

The Directors of Benitec Limited (ASX:BLT)(PINK:BNIKF) provide the following update on the US patent re-examination of the '099 Graham patent.

The Directors of Benitec Limited (ASX:BLT)(PINK:BNIKF) provide the following update on the US patent re-examination of the '099 Graham patent.

Leading developer of RNA interference (RNAi)-based therapeutics Benitec Limited (ASX:BLT)(PINK:BNIKF) announced today that it has, with immediate effect, implemented steps to further reduce its cash burn. These measures are designed to guarantee that the Company maintains sufficient funding to finance its near term key activities including ongoing negotiations with CSIRO, IP prosecution and maintenance and the City of Hope collaboration.

We have successfully strengthened the Benitec team during the past year. Our CEO Sue MacLeman was appointed a Director of the Company and Mel Bridges joined the Board as a Non-Executive Director. We also appointed Dr Jason Smythe as Chief Scientific Officer.

Benitec Limited (ASX:BLT)(PINK:BNIKF) today announced that a key patent focused on producing Double-Stranded Nucleic Acid constructs for therapeutic and related applications of RNA interference (RNAi) had been granted in Singapore.

Leading developer of RNA interference (RNAi)-based therapeutics Benitec Limited (ASX:BLT)(PINK:BNIKF) announced today that Dr John Zaia, had presented an update on the human HIV trial at the 2nd Annual Cambridge Healthtech Institute's "RNAi for Therapeutics" conference held in Boston, MA USA 22-23rd October 2008.

The Directors of Benitec Limited (ASX:BLT)(PINK:BNIKF) are pleased to announce a placement of 43,793,232 shares and one for one free attaching options to raise AUD$1.97 million.

Benitec Limited (ASX:BLT)(PINK:BNIKF) today announced that a key patent "Control of Gene Expression" part of the Graham patent family of RNA interference (RNAi) patents was granted in New Zealand. The "Control of Gene Expression patent" is a patent in the foundational Graham RNAi patent family and is related to the '099 patent currently under reexamination at the USPTO.